A new study from the Perelman School of Medicine at the University of Pennsylvania raises important questions about the safety of psychiatric medication use among children, adolescents, and young adults.
Published in the Journal of the American Academy of Child & Adolescent Psychiatry, the study examined trends in psychotropic medication use in Americans ages 6 to 24 over nearly two decades. Using nationally representative data from the National Health and Nutrition Examination Survey (NHANES), researchers analyzed patterns between 2001 and March 2020.
Their findings reveal two parallel trends: psychotropic medication use has increased steadily among young people, and a substantial portion of those receiving treatment are taking combinations of drugs associated with major drug–to-drug interaction risks.
Rising Use of Psychiatric Medications
The percentage of young people using at least one psychotropic medication rose from approximately 5.3% in the early 2000s to 8.3% by 2020. Increases were observed across multiple medication classes, including stimulants for ADHD, antidepressants, antipsychotics, and mood or anxiety medications. Stimulant use in particular nearly doubled over the study period.
These numbers reflect improved recognition of mental health conditions and expanded access to treatment. For many patients, psychotropic medications are essential and life-changing. But as prescribing grows, so does the complexity of managing those regimens safely.
A Concerning Rate of High-Risk Combinations
The most striking finding was that roughly one in four (26%) young people taking psychotropic medications were prescribed multiple drugs that carry a known risk of major interactions.
Certain combinations, especially those involving antidepressants and antipsychotics, can increase the risk of serious complications such as abnormal heart rhythms, excessive sedation, and serotonin syndrome. While combination therapy can be clinically appropriate in some cases, particularly when single medications are insufficient, it requires careful monitoring and coordination.
Young patients are especially vulnerable because their bodies are still developing, and long-term safety data on some combinations remains limited.
The Challenge of Coordination
In theory, electronic health records and pharmacy systems are designed to flag dangerous drug interactions. In practice, care is often fragmented. A young person may see a pediatrician, a psychiatrist, and possibly other specialists—sometimes across different health systems. Medication lists can become outdated, incomplete, or inconsistent.
As mental health treatment becomes more personalized and complex, polypharmacy has become more common. But oversight mechanisms have not always kept pace with this complexity.
The study underscores the importance of routine medication review, cross-provider coordination, and clear communication with families.
How Technology Can Help Reduce Risk
As medication regimens become more complex, safety increasingly depends on visibility and coordination.
This is where platforms like EveryDose can play an important role. By centralizing medication information in one accessible location, EveryDose helps patients, families, and care teams maintain an accurate, up-to-date medication list. Real-time drug interaction alerts can surface potential risks, while digital adherence tracking provides insight into how medications are actually being taken—not just how they were prescribed.
For health systems and care teams, enhanced medication visibility allows for more proactive oversight, particularly in patients taking multiple psychotropic medications. Instead of relying solely on prescribing-time alerts, clinicians can monitor trends, review regimens over time, and identify high-risk combinations before complications occur.
For families, having a clear, consolidated medication record empowers better conversations with providers. When a child or young adult is prescribed more than one psychiatric medication, being able to see the full regimen—along with education and interaction information—can help reduce uncertainty and improve shared decision-making.
Psychotropic medications are an essential part of modern mental health care. The challenge is not whether to use them—but how to use them safely. As this study highlights, the answer increasingly lies in better coordination, better data, and smarter medication management.